BIOMAT Database Logo BIOMAT Database Logo

Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. 1982

G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp

The new selective 5-HT2 receptor blocking agent ketanserin was given in a dose of 10 mg intravenously to 12 patients with essential hypertension. It caused a distinct fall in supine systemic arterial, right atrial, pulmonary artery, and pulmonary capillary "wedge" pressures. Cardiac output, renal blood flow, and glomerular filtration rate showed no persistent changes. Thus 5-HT2 receptor blockade caused dilatation of both resistance and capacitance vessels and of the renal vascular bed. Heart rate and plasma concentrations of renin and noradrenaline rose after ketanserin. These data suggest that 5-HT may have a role in maintaining high blood pressure.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007650 Ketanserin A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione,R-41,468,R-41468,R 41,468,R 41468,R41,468,R41468
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010880 Piperidines A family of hexahydropyridines.
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D005260 Female Females

Related Publications

G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
February 1984, Arthritis and rheumatism,
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Ketanserin: a selective antagonist of 5-HT2 serotoninergic receptors.
February 1983, Lancet (London, England),
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
October 1982, British medical journal (Clinical research ed.),
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Vascular activity of ketanserin (R 41 468), a selective 5-HT2 receptor antagonist.
April 1981, Archives internationales de pharmacodynamie et de therapie,
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
January 1983, Acta medica Scandinavica,
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Haemorheological effects of ketanserin, a selective 5-HT2 receptor antagonist, in aged, spontaneously hypertensive dogs.
July 1982, Archives internationales de pharmacodynamie et de therapie,
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.
December 2008, European journal of pharmacology,
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
January 1985, Journal of cardiovascular pharmacology,
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.
January 1983, Journal of cardiovascular pharmacology,
G J Wenting, and A J Man in 't Veld, and A J Woittiez, and F Boomsma, and M A Schalekamp
Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
January 1984, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!